

SEATTLE GENETICS INC /WA  
Form SC 13D/A  
December 17, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)

**Seattle Genetics, Inc**  
(Name of Issuer)

**Common Stock, par value \$0.001 per share**  
(Title of Class of Securities)

**812578102**  
(CUSIP Number)

**Leo Kirby**  
**667 Madison Avenue, 21st Floor**  
**New York, NY 10065**  
**(212) 339-5633**  
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**December 12, 2013**  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 812578102 Page 2 of 12 Pages

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Baker Bros. Advisors LP

**1**

13-4093645

(a) "

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) "

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**

OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**

Delaware

**NUMBER OF**      **7** **SOLE VOTING POWER**  
**SHARES**  
**BENEFICIALLY**  
**OWNED BY**  
**EACH**                      20,735,926

**REPORTING  
PERSON  
WITH**

SHARED VOTING POWER

**8**  
0

SOLE DISPOSITIVE POWER

**9**  
20,735,926

**10** SHARED DISPOSITIVE POWER

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**  
20,735,926

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)  
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**  
16.9%(1)

TYPE OF REPORTING PERSON (See Instructions)

**14**  
IA

(1) Based on 122,481,320 shares of the Issuer's common stock outstanding as of November 5, 2013, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 8, 2013.



SCHEDULE 13D

CUSIP No. 812578102 Page 3 of 12 Pages

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Baker Bros. Advisors (GP) LLC

**1**

46-37147749

(a) "

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) "

**3** SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

**4**

OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

**6**

Delaware

**NUMBER OF**      **7** **SOLE VOTING POWER**  
**SHARES**  
**BENEFICIALLY**  
**OWNED BY**  
**EACH**                      20,735,926

**REPORTING  
PERSON  
WITH**

SHARED VOTING POWER

**8**  
0

SOLE DISPOSITIVE POWER

**9**  
20,735,926

**10** SHARED DISPOSITIVE POWER

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**  
20,735,926

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)  
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**  
16.9%(1)

TYPE OF REPORTING PERSON (See Instructions)

**14**  
IA

(1) Based on 122,481,320 shares of the Issuer's common stock outstanding as of November 5, 2013, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 8, 2013.

SCHEDULE 13D

CUSIP No. 812578102 Page 4 of 12 Pages

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

**1**  
Julian C. Baker

(a) "

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) "

**3** SEC USE ONLY  
SOURCE OF FUNDS (See Instructions)

**4**  
OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)  
CITIZENSHIP OR PLACE OF ORGANIZATION

**6**  
United States

SOLE VOTING POWER

**7**  
20,831,166

**8** SHARED VOTING POWER  
NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH



0

SOLE DISPOSITIVE POWER

**9**

20,831,166

SHARED DISPOSITIVE POWER

**10**

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

20,831,166

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ..

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

17.0%(1)

TYPE OF REPORTING PERSON (See Instructions)

**14**

IN, HC

(1) Based on 122,481,320 shares of the Issuer's common stock outstanding as of November 5, 2013, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 8, 2013.

SCHEDULE 13D

CUSIP No. 812578102 Page 5 of 12 Pages

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

**1**  
Felix J. Baker

(a) "

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) "

**3** SEC USE ONLY  
SOURCE OF FUNDS (See Instructions)

**4**  
OO

**5** CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)  
CITIZENSHIP OR PLACE OF ORGANIZATION

**6**  
United States

SOLE VOTING POWER

**7**  
20,943,673(1)

**8** SHARED VOTING POWER  
NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

0

SOLE DISPOSITIVE POWER

**9**

20,943,673(1)

SHARED DISPOSITIVE POWER

**10**

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

20,943,673(1)

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See ..  
Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

17.1%(2)

TYPE OF REPORTING PERSON (See Instructions)

**14**

IN, HC

(1) Includes 112,500 shares of the Issuer's common stock underlying 112,500 options directly held.

(2) Based on 122,481,320 shares of the Issuer's common stock outstanding as of November 5, 2013, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 8, 2013.

SCHEDULE 13D

CUSIP No. 812578102 Page 6 of 12 Pages

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

FBB2, LLC

1

45-5474130

(a) "

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(b) "

3 SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

4

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) ..  
OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

6

Delaware

|  |   |                             |
|--|---|-----------------------------|
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON | 7 | SOLE VOTING POWER<br>18,243 |
|--|---|-----------------------------|

**WITH**

SHARED VOTING POWER

**8**

0

SOLE DISPOSITIVE POWER

**9**

18,243

**10** SHARED DISPOSITIVE POWER

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**11**

18,243

**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ..

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

**13**

(1)

TYPE OF REPORTING PERSON (See Instructions)

**14**

OO

(1) The percentage of ownership is less than 0.1%. (2) Based on 122,481,320 shares of the Issuer's common stock outstanding as of November 5, 2013, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 8, 2013.



**Amendment No. 8 to Schedule 13D**

This Amendment No. 8 to Schedule 13D amends and supplements the statements on the previously filed Schedules 13D filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker, Felix J. Baker and FBB2, LLC (“FBB2”) (collectively the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

The Adviser GP is the sole general partner of the Adviser. Pursuant to the amended and restated management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”), 14159, L.P. (“14159”), and 667, L.P. (“667”, and together with Life Sciences and 14159, the “Funds”), and their respective general partners, the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

**Item 5. Interest in Securities of the Issuer.**

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 8 are incorporated herein by reference. Set forth below is the aggregate number and percentage of shares of Common Stock directly held, as of the date hereof, by each of the following based upon 122,481,320 shares outstanding as of November 5, 2013, as reported in the Issuer’s Form 10-Q filed with the SEC on November 8, 2013. Such percentage figures were calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934 (the “Exchange Act”).

| Reporting Person                   | Number of Shares | Percentage of Class Outstanding |   |
|------------------------------------|------------------|---------------------------------|---|
| 667, L.P.                          | 3,868,576        | 3.2                             | % |
| Baker Brothers Life Sciences, L.P. | 16,509,798       | 13.5                            | % |
| 14159, L.P.                        | 357,552          | 0.3                             | % |

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities held by each of the Funds, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for

purposes of Section 13(d) or for any other purpose.

As discussed above, Julian C. Baker and Felix J. Baker are also the sole managers of FBB2 and as such may be deemed to be beneficial owners of shares owned by FBB2 and may be deemed to have the power to vote or direct the vote and dispose or direct the disposition of those shares.

Felix J. Baker is a Director of the Issuer.

Page 7 of 7 Pages



(c) Felix J. Baker serves on the Issuer's Board as representatives of the Funds. Due to the agreements and policies of the Funds, Felix J. Baker does not have any right to receive any profits from any securities as compensation for serving as a Director of the Issuer and therefore has no pecuniary interest in the restricted stock units payable solely in common shares of the Issuer ("Restricted Stock") or in the options to purchase common stock of the Issuer ("Stock Options"). The Funds are entitled to the pecuniary interest in the Restricted Stock and Stock Options as each holds an indirect pecuniary interest. Felix J. Baker solely as a result of his ownership interest in the general partners of the general partners of the Funds may be deemed to have an indirect pecuniary interest in the Restricted Stock and Stock Options (ie. no direct pecuniary interest). Felix J. Baker currently retains voting and investment power over the shares of Restricted Stock and Stock Options.

The following transactions in the Issuer's Common Stock were effected by the Funds noted below during the sixty days preceding the filing of this statement using working capital of the applicable purchasing Fund. All transactions were effected in the over-the-counter market directly with a broker-dealer. Except as disclosed herein or in any previous amendments to this Schedule 13D, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

| Name                               | Date       | Number of Shares | Transaction | Price/ Share | Footnotes |
|------------------------------------|------------|------------------|-------------|--------------|-----------|
| Baker Brothers Life Sciences, L.P. | 12/3/2013  | 112,797          | Purchase    | 42.3098      | 1         |
| 14159, L.P.                        | 12/3/2013  | 2,816            | Purchase    | 42.3098      | 1         |
| Baker Brothers Life Sciences, L.P. | 12/3/2013  | 105,414          | Purchase    | 42.413       | 2         |
| 14159, L.P.                        | 12/3/2013  | 2,632            | Purchase    | 42.413       | 2         |
| Baker Brothers Life Sciences, L.P. | 12/3/2013  | 142,220          | Purchase    | 42.5595      | 3         |
| 14159, L.P.                        | 12/3/2013  | 3,551            | Purchase    | 42.5595      | 3         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 11,617           | Purchase    | 42.653       | 4         |
| 14159, L.P.                        | 12/4/2013  | 290              | Purchase    | 42.653       | 4         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 18,232           | Purchase    | 42.645       | 5         |
| 14159, L.P.                        | 12/4/2013  | 455              | Purchase    | 42.645       | 5         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 72,807           | Purchase    | 43.2049      | 6         |
| 14159, L.P.                        | 12/4/2013  | 1,818            | Purchase    | 43.2049      | 6         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 40,471           | Purchase    | 43.0056      | 7         |
| 14159, L.P.                        | 12/4/2013  | 1,011            | Purchase    | 43.0056      | 7         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 13,632           | Purchase    | 43.7189      | 8         |
| 14159, L.P.                        | 12/4/2013  | 340              | Purchase    | 43.7189      | 8         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 100,626          | Purchase    | 42.9471      | 9         |
| 14159, L.P.                        | 12/4/2013  | 2,512            | Purchase    | 42.9471      | 9         |
| Baker Brothers Life Sciences, L.P. | 12/4/2013  | 6,814            | Purchase    | 43.4247      | 10        |
| 14159, L.P.                        | 12/4/2013  | 170              | Purchase    | 43.4247      | 10        |
| Baker Brothers Life Sciences, L.P. | 12/5/2013  | 114,663          | Purchase    | 44.0455      | 11        |
| 14159, L.P.                        | 12/5/2013  | 2,863            | Purchase    | 44.0455      | 11        |
| Baker Brothers Life Sciences, L.P. | 12/5/2013  | 22,147           | Purchase    | 43.9995      | 12        |
| 14159, L.P.                        | 12/5/2013  | 553              | Purchase    | 43.9995      | 12        |
| Baker Brothers Life Sciences, L.P. | 12/5/2013  | 219,958          | Purchase    | 43.9752      | 13        |
| 14159, L.P.                        | 12/5/2013  | 5,492            | Purchase    | 43.9752      | 13        |
| Baker Brothers Life Sciences, L.P. | 12/12/2013 | 122,660          | Purchase    | 39.5283      | 14        |

Edgar Filing: SEATTLE GENETICS INC /WA - Form SC 13D/A

|                                    |            |        |          |         |    |
|------------------------------------|------------|--------|----------|---------|----|
| 14159, L.P.                        | 12/12/2013 | 3,056  | Purchase | 39.5283 | 14 |
| Baker Brothers Life Sciences, L.P. | 12/12/2013 | 55,256 | Purchase | 39.537  | 15 |
| 14159, L.P.                        | 12/12/2013 | 1,377  | Purchase | 39.537  | 15 |
| Baker Brothers Life Sciences, L.P. | 12/12/2013 | 99,775 | Purchase | 39.7    | 16 |
| 14159, L.P.                        | 12/12/2013 | 2,486  | Purchase | 39.7    | 16 |
| Baker Brothers Life Sciences, L.P. | 12/13/2013 | 42,646 | Purchase | 39.6549 | 17 |
| 14159, L.P.                        | 12/13/2013 | 1,063  | Purchase | 39.6549 | 17 |
| Baker Brothers Life Sciences, L.P. | 12/16/2013 | 51,244 | Purchase | 39.9219 | 18 |
| 14159, L.P.                        | 12/16/2013 | 1,280  | Purchase | 39.9219 | 18 |
| Baker Brothers Life Sciences, L.P. | 12/16/2013 | 25,596 | Purchase | 39.9121 | 19 |
| 14159, L.P.                        | 12/16/2013 | 639    | Purchase | 39.9121 | 19 |

Page 8 of 8 Pages

(1) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$41.87 to \$42.70. The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(2) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$41.87 to \$42.69. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(3) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$42.39 to \$42.66. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(4) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$42.32 to \$43.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(5) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$43.55 to \$43.70 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(6) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$42.91 to \$43.70 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(7) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$42.69 to \$43.65 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(8) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$43.70 to \$43.73 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(9) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$42.34 to \$43.30 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(10) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$43.39 to \$43.57 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(11) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$43.50 to \$44.29 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(12) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$43.99 to \$44.00 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(13) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$43.61 to \$44.30 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(14) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$39.26 to \$39.79 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

Page 10 of 10 Pages

(15) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$39.40 to \$39.65 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(16) All of the shares traded in this transaction were traded in a single execution at the reported price of \$39.70.

(17) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$39.19 to \$40.00 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(18) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$39.77 to \$40.00 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(19) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$39.80 to \$40.00 The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

Certain securities of the Issuer are held directly by 14159, a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

(e) Not applicable.

**Item 7. Material to Be Filed as Exhibits.**

Exhibit 99.1 Agreement regarding the joint filing of this statement.

Page 11 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 16, 2013

**BAKER BROS.  
ADVISORS LP**

By: Baker Bros. Advisors  
(GP) LLC, its general  
partner

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

**BAKER BROS.  
ADVISORS (GP) LLC**

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

/s/ Julian C. Baker  
Julian C. Baker

/s/ Felix J. Baker  
Felix J. Baker

FBB2, LLC

By: /s/ Julian C. Baker  
Name: Julian C. Baker  
Title: Manager